Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant...
-
Upload
olivia-sweeney -
Category
Documents
-
view
222 -
download
1
Transcript of Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant...
![Page 1: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/1.jpg)
Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol
Targets
Nemanja Stojanović
Consultant Endocrinologist
Queen’s Hospital, Romford
![Page 2: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/2.jpg)
We will talk about
• Kidney in Diabetes
• Drug related renal injury in T2DM
• Preventing DM Nephropathy
• Cholesterol/ BP/ Glucose Treatment
• Guidelines/ Conclusion
![Page 3: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/3.jpg)
Nephropathy
• 35-50% with Type 1 after 20 years of disease
• 10- ? 20% Type 2 patients on diagnosis
![Page 4: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/4.jpg)
Nephropathy: aetiology
• HbA1c >7–8%
• Genetic factors
• Hypertension
• Inflammation
• Altered vascular permeability
• Hyperlipidaemia
• Excessive protein intake
![Page 5: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/5.jpg)
Determinants of Glomerular Proteinuria
• Mean transcapillary hydraulic-pressure difference
• Glomerular surface area• Size selectivity of the glomerular filter• Charge selectivity
![Page 6: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/6.jpg)
Microalbuminuria
• Normoalbuminuria <30 mg/day
• Microalbuminuria 30–300 mg/day
• Clinical or macroalbuminuria >300 mg/day- POINT OF NO RETURN
• ACR
![Page 7: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/7.jpg)
Nephropathy: Patient Should Know…
• Optimal glycaemic control will prevent it or delay it
• Annual urine test: only way to detect it
• Importance of BP monitoring
• Hypertension: predisposes and aggravates nephropathy
![Page 8: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/8.jpg)
Microalbuminuria: Type 2 DM
• 10% have it at diagnosis
• 80% CVS mortality over 10 years
• Associated with insulin resistance sy
• 2 positive samples required for the diagnosis
![Page 9: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/9.jpg)
STENO-2 Study
• 160 patients with T2DM and microalbuminuria
• 80 treated according to the national guidelines + 80 active treatment
• Active group reviewed 3 monthly
• Duration: 7.8 years
NEJM 2003; 348: 383- 93
![Page 10: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/10.jpg)
STENO-2 Study
• Intensive glycaemic control A1c < 7.5 or 6.5%• Systolic Bp < 140 or 130 mmHg• Diastolic BP < 85 or 80 mm Hg• Cholesterol < 4.9 or 4.6 mmol/l• Triglycerides < 1.7mol/l
• Most active treatment patients were on Aspirin
NEJM 2003; 348: 383- 93
![Page 11: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/11.jpg)
STENO-2 Endpoints
• Composite death from CVS causes• CVG• PTCA• Nonfatal CVA• Amputation• Vascular surgery to correct ischaemia
• Microvascular
NEJM 2003; 348: 383- 93
![Page 12: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/12.jpg)
STENO-2
• After the end of the study
• Prospective follow up for 5.5 years
• Both groups now treated to the national targets
![Page 13: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/13.jpg)
Preventing Microalbuminuriaand Progression of Diabetic
Nephropathy: Antihypertensives
![Page 14: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/14.jpg)
Preventing Microalbuminuria in T2DM: BENEDICT Study
• 1204 Hypertensive Subjects with T2DM
• No microalbuminuria
• Target BP 120/80
• HbA1c ~ 5.8± 1.5%
• Duration of Diabetes< 25 years
NEJM 351: 1941-51; 2004
![Page 15: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/15.jpg)
Preventing Microalbuminuria in T2DM
Trandolapril Trandolapril + Verapamil
Verapamil Placebo
N= 301 300 303 300
Microalb-uminuria
6% 5.7% 11.9% 10%
BP over baselinemmHg
151/87 151/87 150/87 152/87
NEJM 351: 1941-51; 2004
![Page 16: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/16.jpg)
Irbesartan in T2DM Nephropathy
• 1715 pts- duration 2.6 years• Irbesartan 300mg OD vs Amlodipine OD vs
Placebo• Proteinuria 900mg/day• Cr ♀ 88- 265 umol/l ♂ 107- 265 umol/l• Target BP 135/85 mmHg• Primary composite outcome: ESRF, doubling of
Cr & Death: any cause
NEJM 2001; 345: 851-61
![Page 17: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/17.jpg)
Irbesartan in T2DM Nephropathy
Irbesartan Amlodipine Placebo
N 579 567 569
BP achieved
140/ 77 mmHg
141/ 77 mmHg
144/ 82 mmHg
•Renal Outcome Irbesartan group 23% better
than Amlodipine and 20% than Placebo• CVS mortality: no difference
NEJM 2001; 345: 851-61
![Page 18: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/18.jpg)
Losartan and Diabetic Nephropathy
• Secondary outcomes- Composite of morbidity and mortality from
cardiovascular causes (p=NS)
- Proteinuria Losartan: 35% reduction
- Progression of renal disease Losartan: 18% reduction
NEJM2008 358: 2433-2446
![Page 19: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/19.jpg)
Irbesartan
• In patients with microalbuminuria
• Renoprotective, prevents albuminuria in hypertensive patients with T2DM
• Higher dose was more effective
• A higher proportion of patients restored normoalbuminuria Irbesartan 300mg OD group than placebo 34% vs 21%
Parving H et al. N Engl J Med 2001;345:870-878
![Page 20: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/20.jpg)
Telmisartan vs Enalapril
• Patients with early diabetic nephropathy
• 250 subject over 5 years
• Similar decrements in GFR in both groups: -17.9 ml/min/1.73m2 of body surface area
• Cr, AER no difference
N Engl J Med 2004; 351:1952-61
![Page 21: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/21.jpg)
Drugs: Frequent Offenders
• Iodine based contrast• Metformin & Contrast• NSAIDS & COX-2 Inhibitors• ACE• ARBs• Aminoglycoside antibiotics• Amphotericin B• Immunosuppressants
![Page 22: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/22.jpg)
Lipids ± Diabetes
![Page 23: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/23.jpg)
At least One Complication
• Hypertension• Retinopathy/ Maculopathy/ Previous laser• Smoking• Micro or macroalbuminuria
• LDL < 4.14 mmol/l• Triglycerides< 6.78mmol/l
The Lancet 2004; 364: 685 - 696
![Page 24: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/24.jpg)
CARDSRisk Factors
1
2
34
63%30%
6%
1%
The Lancet 2004; 364: 685 - 696
![Page 25: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/25.jpg)
Primary Endpoints
• Acute coronary heart disease event (incl. MI, silent MI, unstable angina, death, CPR)
• Coronary revascularisation procedures
• Stroke
The Lancet 2004; 364: 685 - 696
![Page 26: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/26.jpg)
Primary Endpoints: Results
No difference between the sexes or risk factor subgroups
• Acute coronary heart disease event 36%
• Coronary revascularisation procedures 31%• Stroke
48%
The Lancet 2004; 364: 685 - 696
![Page 27: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/27.jpg)
CARDS
• LDL < 2.6mmol subgroup
• 743 patients
• 26% reduction in major cardiovascular events
The Lancet 2004; 364: 685 - 696
![Page 28: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/28.jpg)
REVERSAL Trial
• Endovascular USS• Pravastatin 40mg vs Atorvastatin 80mg OD• Baseline LDL: 3.89mmol/l
• End of Study LDL: Pravastatin 2.85mmol/l Atorvastatin 2.05mmol/l• After 18/12 atheroma progressed in pravastatin
group but not in Atorvastatin group
JAMA. 2004; 291:1071-1080
![Page 29: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/29.jpg)
Drugs on Offer
• Simvastatin
• Atorvastatin
• Pravastatin
• Rosuvastatin
• Ezetamibe
• Niacin
• Fibrates
• Omacor
• Diet
![Page 30: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/30.jpg)
Equivalent Doses
Dose LDL Reduction %
Atorvastatin+ 10 39
Simvastatin 20-40 35-41
Pravastatin 40 34
Rosuvastatin 5-10 39-45
Fluvastatin 40-80 25-35
Ezetamibe 10 16-18 (12-21c)
+ + max dose decreases the LDL by additional 20%max dose decreases the LDL by additional 20%
![Page 31: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/31.jpg)
Metabolism
Atorvastatin cytochrome P 450 3A4
Simvastatin cytochrome P 450 3A4
Pravastatin 70% faeces, 20 % urine; 7 different sets of enzymes
Rosuvastatin 90% unchanged in faeces
Fluvastatin 2C9 isozyme systems (75%)
Ezetamibe 70 % faeces unchanged; conjugation with glucuronide
![Page 32: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/32.jpg)
Effect of reduction of LDL by 1mmol/l by any means on coronary death and non-fatal MI:
meta-analysis of 58 trials0%
5%
10%
15%
20%
25%
30%
35%
40%
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Law MR BMJ 2003, 326: 1423-9
![Page 33: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/33.jpg)
Ahead of the Press
![Page 34: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/34.jpg)
ADVANCE
• 11140 patients: 5 years
• Intensive glycaemic control (A1c 6.5%) vs Conventional (A1c 7.3%)
• Intensive group: gliclazide MR 30 to 120 mg daily and other hypoglycamic agents including insulin
N Engl J Med 2008;10.1056/NEJMoa0802987
![Page 35: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/35.jpg)
ADVANCE Primary Endpoints
• Composite of macro and microvascular events considered jointly and separately
• Macro: CVD death, non fatal CVA & MI
• Micro:new or worsening nephropathy ; doubling of the serum creatinine; the need for dialysis; death due to renal causes; worsening of retinopathy
N Engl J Med 2008;10.1056/NEJMoa0802987
![Page 36: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/36.jpg)
ADVANCEIntensive Rx Conventional Rx
n 5571 5569
Study End A1c 6.5% 7.3%
Gliclazide MR 90% (30-120mg OD) NA
Insulin 40.5% 24.1%
Weight > 0.7kg
Prim outcome 18.1% 20%
N Engl J Med 2008;10.1056/NEJMoa0802987
![Page 37: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/37.jpg)
ADVANCE Conclusion
• The main contributor to the 10% relative reduction in the primary outcome found with intensive control as compared with standard control was a 21% relative reduction in the risk of new or worsening nephropathy
• More modest but significant reduction in microalbuminura
N Engl J Med 2008;10.1056/NEJMoa0802987
![Page 38: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/38.jpg)
ACCORD Trial
• 10,251 patients• Intensive glycaemic control and CVS outcomes• Primary outcomes : CVD death, Non fatal CVA &
MI• Intensive Treatment: HbA1c< 6%• Conventional Treatment HbA1c 7-7.9• Death rates begin to separate after 1 year…..
N Engl J Med 2008;10.1056/NEJMoa0802743
![Page 39: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/39.jpg)
ACCORD
Intensive (%) Conventional(%)n 5128 5123
Hypoglycaemia 538 (10.5) 179 (3.5)
Weight gain> 10kg 1399 (27.8) 713 (14.1)
CVD Death 135 (2.6) 94 (1.8)
Non fatal MI 186 (3.6) 235 (4.6)
Non fatal CVA 67 (1.3) 61 (1.2)
Any Death 257 (5) 203 (4) N Engl J Med 2008;10.1056/NEJMoa0802743
![Page 40: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/40.jpg)
NICE
BP < 130/80
ACE/ ARB
Cholesterol<4mmol/l
LDL< 2mmol/l
Aspirin
![Page 41: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/41.jpg)
Instead of Conclusion
• If I had T2DM and microalbuminuria:
- BP 129 (114)/ 79 mmHg
- LDL < 2mmol/l
- ACE or ARB
- Aspirin
![Page 42: Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.](https://reader033.fdocuments.us/reader033/viewer/2022061305/5514389e550346dd488b6346/html5/thumbnails/42.jpg)
www.EndoDiabetes.com